MCIM
YMAB

Meadow Creek Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Meadow Creek Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Sell
848
-320
-27% -$8.18K ﹤0.01% 1317
2019
Q2 		$27K Sell
1,168
-800
-41% -$18.4K ﹤0.01% 1313
2019
Q1 		$52K Hold
1,968
– – ﹤0.01% 1268
2018
Q4 		$40K Sell
1,968
-2,208
-53% -$50.7K ﹤0.01% 1229
2018
Q3 		$111K Buy
+4,176
New +$106K ﹤0.01% 1211

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Meadow Creek Investment Management's YMAB Position: Q3 2019 in Review

Meadow Creek Investment Management reduced its Y-mAbs Therapeutics (YMAB) stake by 27% in Q3 2019, selling an estimated $8.18K and leaving 848 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Meadow Creek Investment Management first reported a position in YMAB in Q3 2018 and has held it in 5 quarters since. The position peaked at $111K in Q3 2018. 65 funds tracked by Wall St. Rank hold YMAB as of Q3 2019.

  • Meadow Creek Investment Management held 848 shares of Y-mAbs Therapeutics worth $22K as of Q3 2019.
  • Meadow Creek Investment Management sold 320 Y-mAbs Therapeutics shares in Q3 2019, an estimated $8.18K.
  • Y-mAbs Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1317 holding.
  • Meadow Creek Investment Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and has held it in 5 quarters since.
  • Meadow Creek Investment Management's Y-mAbs Therapeutics position peaked at $111K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.